Home › Free Stock Grades › NTLA
Intellia Therapeutics, Inc. (NTLA) Stock Grade
NTLA · Healthcare
C
Market Cap
$1.6B
P/E Ratio
—
Revenue Growth (YoY)
+16.9%
Net Margin
-609.9%
Return on Equity
—
Dividend Yield
None
About Intellia Therapeutics, Inc.'s fundamentals
Intellia Therapeutics is a biotechnology company with a market capitalization of $1.6 billion that generated year-over-year revenue growth of 16.9%. However, the company is currently unprofitable, operating at a net margin of -609.9%, and reported a net loss in its latest annual statement, indicating it is in a development stage with expenses significantly outpacing revenues. The company does not pay a dividend, which is typical for early-stage biotech firms reinvesting resources into research and drug development.